Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT in Germany: Two sides of two different coins

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 4, 2012, Pages 723-724

  Ruf, Juri ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 68; INDIUM 111; OCTREOTIDE; TETRAXETAN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND; PENTETIC ACID;

CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG COST; GERMANY; LETTER; NEUROENDOCRINE TUMOR; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ECONOMICS; FEMALE; HUMAN; MALE; NOTE; PANCREAS TUMOR; PATHOLOGY; SCINTISCANNING;

FEMALE; HUMANS; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84862576171     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2010-y     Document Type: Letter

References (4)

1. Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, et al. Cost comparison of (111)In-DTPA-octreotide scintigraphy and (68)Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39(1):72-82.
2. Wong KK, Wynn EA, Myles J, Ackermann RJ, Frey KA, Avram AM. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors. Clin Nucl Med 2011; 36(1):25-31.
3. BGBl. I, 22 July 2009; p. 1990
4. 2 No. 3, AMVHV, amendment I, BAnz, 6 August 2009, p. 2890